Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.73 |
| ▸ | ALPI | P09923 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | XIAP | P98170 | 1/20 | 0.73 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.58 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPA3 | P15088 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL29211050 | 1.00 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL22556045 | 1.00 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL27864433 | 0.95 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL398714 | 0.95 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL7248684 | 0.95 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL27548157 | 0.95 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL1897792 | 0.95 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL13835334 | 0.93 | SLC7A5 (0.79) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL1637917 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1011892 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003406-B | Heteroaryl ring nitroxide compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023125803-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-116003406-A | Heteroaryl ring nitroxide compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115702932-A | Application of RNA editing related enzyme function blocker and drug screening method | 清华大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-104797582-B | Substituted pyrrolo-pyrimidine radicals amino-benzothiazole ketone as MKNK inhibitors of kinases | 拜耳药业股份公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-104797582-A | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | Bayer Pharma AG | 2015-07-22 | — | — | CN | disclosed |
| US-20140234321-A1 | HUNK, A SNF1-RELATED KINASE ESSENTIAL FOR MAMMARY TUMOR METASTASIS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-21 | — | — | US | disclosed |
| US-20120107836-A1 | DEVELOPMENT OF FLUORESCENTLY P-LOOP LABELLED KINASES FOR SCREENING OF INHIBITORS | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2419509-A1 | DEVELOPMENT OF FLUORESCENTLY P-LOOP LABELLED KINASES FOR SCREENING OF INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-20110212475-A1 | Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056023-A2 | THIAZOLE INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006112879-A2 | HUNK, A SNF1-RELATED KINASE ESSENTIAL FOR MAMMARY TUMOR METASTASIS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-10-26 | — | — | WO | disclosed |
| US-7119185-B2 | Hormonally up-regulated, neu-tumor-associated kinase | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-10-10 | — | — | US | disclosed |
| US-7041495-B2 | Pregnancy up-regulated, nonubiquitous CaM kinase | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050265985-A1 | Hormonally up-regulated, neu-tumor-associated kinase | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2005-12-01 | — | — | US | disclosed |
| US-20050186667-A1 | Pregnancy up-regulated, nonubiquitous CaM kinase | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050186668-A1 | HORMONALLY UP-REGULATED, NEU-TUMOR-ASSOCIATED KINASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | SLC7A5 2719/4885ALPI 4716/4885PKM 760/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | SLC7A5 2556/4885ALPI 4529/4885PKM 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.